ArticleJournal of thoracic disease2020
Uncommon
Article in Journal of thoracic disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis.Targeted oncology · 2022Pooled it
- Multimodal scanning of genetic variants with base and prime editing.Nature biotechnology · 2025Article
- Article
- Lung Cancer-Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature).International journal of molecular sciences · 2025Review
- Advanced lung adenocarcinoma with rareAmerican journal of translational research · 2025Article
- Radiomics of metastatic brain tumor as a predictive image biomarker of progression-free survival in patients with non-small-cell lung cancer with brain metastasis receiving tyrosine kinase inhibitors.Translational oncology · 2024Article
- Article
- Role of the TME in immune checkpoint blockade resistance of non-small cell lung cancer.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- Identification of potential inhibitors for drug-resistant EGFR mutations in non-small cell lung cancer using whole exome sequencing data.Frontiers in pharmacology · 2024Article
- Hope and Challenges: Immunotherapy inBiomedicines · 2023Review
- Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study.BMC cancer · 2023Article
- Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review.Current oncology (Toronto, Ont.) · 2023Review
- All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations.Journal of cancer research and clinical oncology · 2023Article
- [Correlation between Immune Microenvironment Features and EGFR Mutation Status in Lung Adenocarcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- A L833V/H835LHeliyon · 2022Article
- Multiple mutations in theTranslational lung cancer research · 2022Review
- Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort.Journal of thoracic disease · 2022Article
- Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complexJournal of thoracic disease · 2022Article
- Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects.Frontiers in immunology · 2022Review
- Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
methodsThis is a single-center retrospective study of patients with
resultsAmong 6,747 tumor samples, 95 out 820 patients (11.6%) harbored 113 uncommon
conclusionsIn conclusion, uncommon
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.